C Grandclément, C Estoppey, E Dheilly, M Panagopoulou, T Monney, C Dreyfus, J Loyau, V Labanca, A Drake, S De Angelis, A Rubod, J Frei, L N Caro, S Blein, E Martini, M Chimen, T Matthes, Z Kaya, C M Edwards, J R Edwards, E Menoret, C Kervoelen, C Pellat-Deceunynck, P Moreau, M L Mbow, A Srivastava, M R Dyson, E A Zhukovsky, M Perro, S Sammicheli
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malignancies. ISB 1442 consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity-induced blocking of proximal CD47 receptors on the same cell while preventing on-target off-tumor binding on healthy cells...
March 6, 2024: Nature Communications